Pfizer COVID-19 vaccine safety data - People affected by cancer and transplant recipients Pfizer COVID-19 vaccine adult formulation Main navigation COVID-19 vaccines Moderna XBB.1.5 COVID-19 vaccine Pfizer XBB.1.5 COVID-19 vaccine Pfizer bivalent BA.4/5 COVID-19 vaccine Moderna bivalent COVID-19 vaccine Pfizer bivalent BA.1 COVID-19 vaccine Pfizer COVID-19 vaccine adult formulation All participants Aboriginal and Torres Strait Islander participants Adolescent participants People affected by cancer and transplant recipients Pregnant participants Pfizer COVID-19 vaccine paediatric formulation (5–11 years) Moderna COVID-19 vaccine Novavax COVID-19 vaccine AstraZeneca COVID-19 vaccine Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Shingrix® AusVaxSafety has been actively monitoring the short-term adverse event profile of COVID-19 vaccines used in Australia through post-vaccination safety surveys that allow vaccine recipients to report any adverse events they may have experienced at different intervals following vaccination. These surveys also allow individuals to report pre-existing medical conditions, allowing AusVaxSafety to capture COVID-19 vaccine safety data, specific to Australia, for people affected by cancer and transplant recipients.AusVaxSafety captures COVID-19 vaccine safety data for the following cancer and transplant recipient population groups:cancer (not including blood or bone marrow cancer) diagnosed in the last 12 monthsblood cancer (e.g. leukaemia, lymphoma or myelodysplastic syndrome) diagnosed within the last 5 yearsorgan transplant recipients on immune suppressive therapy or bone marrow transplant recipients in the last 2 yearsAusVaxSafety has analysed the data collected from people who reported the above pre-existing conditions and have created infographics outlining the short-term adverse event profile for each group, including a comparison to the general population. These infographics provide individuals affected by cancer and transplant recipients with real-world information on what to expect following Pfizer COVID-19 vaccination and can be used when planning for COVID-19 vaccination.AusVaxSafety has reaffirmed the safety of these vaccines. Data on this page will no longer be updated. Find out more here. Cancer (not including blood or bone marrow cancer) The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publicationAusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Blood cancer The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. Organ transplant or bone marrow transplant recipient The profile of reported events from AusVaxSafety surveillance of the Pfizer (Comirnaty) COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.Read more about how AusVaxSafety is conducting national COVID-19 vaccine safety surveillance in Australia here.Links to further information on the expected profile for the Pfizer (Comirnaty) COVID-19 vaccine are available below: Cancer Australia has developed Frequently Asked Questions (FAQs) about the COVID-19 vaccines for people affected by cancer, including dedicated FAQs for Aboriginal and Torres Strait Islander people, and translations into the ten most commonly spoken languages in Australia other than EnglishAustralian Technical Advisory Group on Immunisation (ATAGI) clinical guidance on use of COVID-19 vaccine in Australia in 2021Guidance on myocarditis and pericarditis after COVID-19 vaccinesComirnaty vaccine phase III trial publication Comparison of Comirnaty and COVID-19 AstraZeneca vaccines in United Kingdom publication AusVaxSafety will continue to closely monitor the safety data of COVID-19 vaccines in use in Australia in conjunction with the TGA. News & events All news & events 08 January 2025 | News New report re-affirms short-term safety of vaccines in Australia 08 November 2024 | News Enhanced National Immunisation Program vaccine safety data now available 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety